Activity of caspofungin and voriconazole against clinical isolates of Candida and other medically important yeasts by the CLSI M-44A disk diffusion method with neo-sensitabs tablets

Chemotherapy

Volumn 54, Issue 1, 2007, Pages 38-42

  Carrillo Munoz A J ^a   Quindos G ^d   Del Valle, O ^b   Santos, P ^e   Giusiano, G ^f   Ezkurra, P A ^d   Estivill, M D ^c   Casals, J B ^g  

^a Associacio Catalana d'Intelligencia Artificial   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Althaia   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

^f UNIVERSIDAD NACIONAL DEL NORDESTE   (Argentina)

^g Rosco Diagnostica   (Denmark)

Author keywords

Amphotericin B; Candida; Caspofungin; Disk diffusion; Fluconazole; Itraconazole; Ketoconazole; Neo Sensitabs; Susceptibility; Voriconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; METHYLENE BLUE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CULTURE MEDIUM; DISK DIFFUSION; DRUG ACTIVITY; FUNGUS ISOLATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA; CRYPTOCOCCUS; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; PYRIMIDINES; RHODOTORULA; TRIAZOLES; TRICHOSPORON;

EID: 37349079990     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112414     Document Type: Article

References (25)

1. Fromtling RA: Overview of medically important azole derivatives. Clin Microbiol Rev 1988;1:187-217.
2. Carrillo-Muñoz AJ, Quindós G, Lopez-Ribot JL: Current developments in antifungal agents: present and future. Curr Med Chem Anti Infec Agents 2004;3:297-323.
3. Onishi J, Meinz M, Thompson J, Curotto J, Dreikorn S, Rosenbach M, Douglas C, Abruzzo G, Flattery A, Kong L, Cabello A, Vicente F, Pelaez F, Diez MT, Martin I, Bills G, Giacobbe R, Dombrowski A, Schwartz R, Morris S, Harris G, Tsipouras A, Wilson K, Kurtz MB: Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000;44:368-377.
4. Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003;48:225-235.
5. Odds FC, Brown AJ, Gow NA: Antifungal agents: mechanisms of action. Trends Microbiol 2003;11:272-279.
6. Wiederhold NP, Lewis RE, Wiederhold NP: The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs 2003;12:1313-1333.
7. User's Guide: Neo-Sensitabs™ Susceptibility Testing, ed 18. Taastrup, Rosco Diagnostica A/S, 2005/2006.
8. Quindós G, Abarca L, Carrillo-Muñoz AJ, Arévalo MP, Bornay FJ, Casals JB, Hernández Molina JM, Iglesias I, Linares MJ, Martín Mazuelos E, Pereiro Ferreirós M, Rezusta A, Rubio MC, Salesa R, San Millán R, Torres Rodríguez JM: Multicenter survey of in vitro antifungal resistance in yeasts of medical importance isolated from Spanish patients. Rev Iberoam Micol 1999;16:102-105.
9. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts: Approved Guideline M44-A. Wayne, National Committee for Clinical Laboratory Standards, 2004.
10. Zone Diameter Criteria for Interpretative Standards and Corresponding Minimal Inhibitory Concentrations (MIC) Interpretative Breakpoints (M44-S1). Wayne, Clinical and Laboratory Standards Institute, 2006.
11. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, Chaturvedi V, Ghannoum MA, Odds FC, Rinaldi MG, Sheehan DJ, Troke P, Walsh TJ, Warnock DW: Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819-826.
12. Carrillo-Muñoz AJ, Tur C, Estivill D, Montsant L, Torres-Rodríguez JM: Evaluación de un método de difusión en agar para el estudio de la sensibilidad in vitro a los antifúngicos frente a cepas de referencia. Rev Esp Quimioter 1995;8:221-228.
13. Carrillo-Muñoz AJ, Abarca L, Quindós G, Arévalo MP, Bornay FJ, Cabañes FJ, Casals JB, Estivill D, González-Lama Z, Iglesias I, Hernández Molina JM, Linares MJ, Martín Mazuelos E, Payá MJ, Pereiro M Jr, San Millán R, Rubio MC: Multicenter evaluation of Neo-Sensitabs, a standardized diffusion method for yeast susceptibility testing. Rev Iberoam Micol 1999;16:92-96.
14. Rementeria A, Sánchez-Vargas LO, Villar M, Casals JB, Carrillo-Muñoz AJ, Rodríguez Andrés C, Eraso E, Quindós G: Comparison of tablet and disk diffusion methods for fluconazole and voriconazole in vitro activity testing against clinical isolates of Candida. J Chemother 2007;19:172-177.
15. Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L: Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol 2006;44:2105-2108.
16. Sandven P: Detection of fluconazole-resistant Candida strains by a disc diffusion screening test. J Clin Microbiol 1999;37:3856-3859.
17. Troillet N, Durussel C, Bille J, Glausser MP, Gham JP: Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV infected patients. Eur J Clin Microbiol Infect Dis 1993;12:911-915.
18. Barry AL, Brown SD: Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J Clin Microbiol 1996;34:2154-2157.
19. Finquelievich JL, Iovannitti CA, Mujica MT, Relloso S, Carnovale S, de Elias Costa MR, Jewtuchowicz V, Espinel-Ingroff A: Susceptibility of Candida species to fluconazole assayed by a disk diffusion method with automated reading versus a microdilution method. Rev Argent Microbiol 2003;35:214-218.
20. Espinel-Ingroff A, Canton E, Gibbs D, Wang A: Correlation of Neo-Sensitabs tablet diffusion assay on three media, with CLSI broth microdilution M27-A2 and disk diffusion M44-A methods for susceptibility testing of Candida spp. and Cryptococcus neoformans, with amphotericin B, caspofungin, fluconazole, itraconazole, and voriconazole. J Clin Microbiol 2007;45:858-864.
21. Carrillo-Muñoz AJ, Cárdenes CD, Carrillo-Orive B, Rodríguez V, del Valle O, Casals J, Quindós G: Antifungal activity of voriconazole against dermatophytes and Scopulariopsis brevicaulis determined by an agar diffusion method (NeoSensitabs®). Rev Iberoam Micol 2005;22:108-111.
22. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J Clin Microbiol 2006;44:760-763.
23. Cheung C, Guo Y, Gialanella P, Feldmesser M: Development of candidemia on caspofungin therapy: a case report. Infection 2006;34:345-348.
24. Giusiano G, Mangiaterra M, Garcia Saito V, Rojas F, Gómez V, Díaz MC: Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients. Chemotherapy 2006;52:254-259.
25. Carrillo-Muñoz AJ, Quindós G, Tur C, Ruesga M, Alonso R, del Valle O, Rodriguez V, Arévalo MP, Salgado J, Martin-Mazuelos E, Bornay-Llinares FJ, Palacio A, Cuétara M, Gasser I, Hernández- Molina JM, Pemán J: Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole. Chemotherapy 2000;46:235-244.